Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Takeda and Lilly remain on the hook for $9B Actos award

Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.

Biotech upstart Dezima will take on Merck and Lilly in PhIII CETP showdown

In one of the most improbable rivalries in the drug development world, tiny Dutch biotech Dezima today laid claim to a successful Phase IIb study of its CETP cholesterol drug TA-8995, putting it on track to a 2015 launch for a Phase III showdown with two giants in the field, Eli Lilly and Merck.

Cost watchdogs bar Boehringer, Lilly's diabetes med Jardiance--for now

Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.

Big Pharma, Big Biotech prepare for showdown in next-gen psoriasis market

The good news for Eli Lilly: Its experimental late-stage psoriasis drug has topped Pfizer and Amgen's blockbuster Enbrel in a head-to-head study. The not-so-good news: It's not the only one.

Jazz Pharmaceuticals joins AstraZeneca and Lilly on Box's client list

Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.

Lilly's strong results for psoriasis drug come on heels of data from Novartis

Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.

Eli Lilly joins list of Enbrel-beaters with head-to-head psoriasis showdown

Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer's Enbrel in a head-to-head study. And Lilly says the results are good enough to back a regulatory filing in the first half of 2015 for its IL-17A therapy as it races to gain some new approvals following a punishing onslaught of generic competition to its top drug franchises.

Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits

Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.

Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path

Eli Lilly has won a "tentative" FDA approval for its knockoff of Sanofi's Lantus, but don't look for it at a pharmacy anytime soon. The insulin glargine injection--to be marketed as Basaglar eventually in the U.S.--faces an automatic 30-month stay after Sanofi filed a suit against Lilly and its partner Boehringer Ingelheim claiming patent infringement.

Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market

The executive team here at the rapidly expanding headquarters of Novo Nordisk doesn't pull many punches. CEO Lars Rebien S ø rensen is a competitive sort who tends to be blunt, aggressive and forward-thinking; projecting a confident attitude that is reflected by the rest of the execs and right down the line to 40,000 rank-and-file employees around the world.